This Advanced master’s degree will allow you to learn about the latest advances in endocrinology, delving into subjects such as thyrotropinomas or radionuclide therapy in pheochromocytomas"

Recent advances in endocrinology and endocrine oncology have improved the diagnostic processes, follow-up and treatment of patients with hormonal and metabolic problems. Thus, at present specialists can incorporate these new developments into their practice, but to do so they need access to a program that is adapted to their needs and professional circumstances. 

This Advanced master’s degree in Clinical Endocrinology will completely suit the physician, as its 100% online teaching methodology has been specifically designed with practicing specialists in mind. This way, you can decide when, where and how to study, without being subjected to uncomfortable commutes or rigid schedules. In addition, you will have at your disposal a prestigious faculty team that will update you with a wide range of multimedia resources: video procedures, analysis of actual clinical cases, master lectures or interactive summaries, among others. 

Thus, thanks to this teaching system, endocrinologists will be able to delve into relevant aspects of the discipline such as the physiology of the menstrual cycle, the molecular aspects of differentiated thyroid carcinoma, the causes of nodular thyroid disease or hereditary disorders of carbohydrate metabolism. 

Incorporate into your daily work the most up-to-date developments in oncology of the endocrine system thanks to this Advanced master’s degree, which is designed using the best multimedia resources" 

This Advanced master’s degree in Clinical Endocrinology contains the most complete and up-to-date scientific program on the market. Its most notable features are

• Case studies presented by experts in endocrinology
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Special emphasis on innovative methodologies in the field of Endocrinology
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

Update yourself in a fast and convenient way thanks to this program, specially designed to bring professionals closer to the latest scientific evidence in this medical field" 

The teaching staff includes medical professionals who bring their experience to this training program, as well as renowned specialists from leading societies and prestigious universities. 

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive training experience designed to train for real-life situations. 

This program is designed around Problem Based Learning, whereby the student must try to solve the different professional practice situations that arise during the academic year. For this purpose, the professional will be assisted by an innovative interactive video system created by renowned and experienced experts.  

TECH online learning system will allow you to choose the time and place to study, without interfering with your work"

You will be accompanied by a highly prestigious faculty team in the field of endocrinology to assist you throughout your learning process"

This Advanced master’s degree in Clinical Endocrinology is composed of 20 specialized modules, and will allow the specialists to delve into issues relevant to this field such as the clinical manifestations and diagnosis of metabolic syndrome, polycystic ovary syndrome and chronic anovulation, gastrointestinal hormones in the control of dietary intake or the indications for the treatment of hyperparathyroidism in patients with MEN 2, among others. 

TECH has assembled the most comprehensive and advanced knowledge in this program, which has been developed into 20 specialized modules"  

Module 1. Hypothalamus, Pituitary Gland and Autoimmune Pathology

1.1. Endocrinology 

1.1.1. Types of Hormones 
1.1.2. Synthesis, Processing and Degradation of Hormones 
1.1.3. Hormone Receptors 
1.1.4. Regulating Systems 
1.1.5. Endocrine Autoimmunity 
1.1.6. Genetic Basis of Endocrine Diseases 

1.2. Endocrine Pathophysiology 

1.2.1. Biosynthesis Disorders 
1.2.2. Secretion Disorders 
1.2.3. Transportation Disorders 
1.2.4. Action Disorders 
1.2.5. Regulatory Disorders 
1.2.6. Autonomous Hormone Production 

1.3. Metabolism, Hormones and Coenzymes 

1.3.1. Nutrients 
1.3.2. Glucose Pathways 
1.3.3. Lipids 
1.3.4. Proteins 
1.3.5. Energy Production and Use 
1.3.6. Specific Metabolic Particularities 

1.4. Hypothalamic and Pituitary Physiology 
1.5. Hypopituitarism 
1.6. Pineal Gland Pathology 
1.7. Pituitary Tumor Syndromes 
1.8. Inadequate ADH Secretion 
1.9. Central Diabetes Insipidus 
1.10. Autoimmune Polyglandular Syndromes 

1.10.1. Autoimmune Polyglandular Autoimmune Syndrome Type 1 
1.10.2. Autoimmune Polyglandular Autoimmune Syndrome Type 2 

Module 2. Thyroid Gland, Parathyroid Gland and MEN

2.1. Physiology and Thyroid Function Tests 
2.2. Goiter and the Euthyroid Patient Syndrome 
2.3. Hypothyroidism 
2.4. Hyperthyroidism 
2.5. Thyroiditis 
2.6. Thyroid Nodule and Thyroid Cancer 
2.7. Biology of Mineral Metabolism 

2.7.1 Parathyroid Hormone 
2.7.2. Vitamin D 
2.7.3. Regulation of Mineral Metabolism 
2.7.4. Laboratory Evaluation of Mineral Metabolism 

2.8. Hypoparathyroidism and Pseudohypoparathyroidism 
2.9. Hyperparathyroidism 

2.9.1. Primary 
2.9.2. Secondary 

2.10. Multiple Endocrine Neoplasms 

2.10.1. Type 1 MEN 
2.10.2. Type 2 MEN 

Module 3. Disorders of the Adrenal Glands 

3.1 Anatomy 
3.2. Physiology of the Adrenal Glands 
3.3. Cushing's Syndrome 
3.4. Adrenal Insufficiency 
3.5. Hyperaldosteronism 
3.6. Hypoaldosteronism 
3.7. Pheochromocytoma 
3.8. Congenital Adrenal Hyperplasia 
3.9. Incidentalomas 
3.10. Tumors and Adrenal Metastases 

Module 4. Obesity, Metabolic Syndrome and Dyslipidemia 

4.1. Epidemiology and Measurement of Obesity 
4.2. Adipocyte, Etiology and Consequences of Obesity 
4.3. Epidemiology and Etiology of the Metabolic Syndrome 
4.4. Pathophysiology of the Metabolic Syndrome 
4.5. Clinical Manifestations and Diagnosis of the Metabolic Syndrome 

4.5.1. Relationship of the Metabolic Syndrome with HTA 
4.5.2. Relationship between the Metabolic Syndrome and Heart Failure 

4.6. Prevention and Treatment of the Metabolic Syndrome 

4.6.1. Importance of Lifestyle 
4.6.2. Vasculoprotective and Etiopathogenic Treatment 

4.7. Lipoprotein Metabolism and Classification of Dyslipidemias 
4.8. Lipid-lowering Drugs and Therapeutic Strategies 
4.9. Dyslipidemia Management in Different Clinical Situations 

4.9.1. Familial Dyslipidemia 
4.9.2. Women 
4.9.3. Elderly people 
4.9.4. Diabetes and the Metabolic Syndrome 
4.9.5. Secondary Prevention 

4.10. Non-pharmacological Methods 

4.10.1. Lifestyle 
4.10.2. Functional Foods 
4.10.3. Medicinal Plants 

Module 5. Diabetes Mellitus 

5.1. Etiology, Classification and Prevalence 
5.2. Etipathogenesis, Insulin Resistance and Metabolic and Molecular Pathogenesis 
5.3. Diabetes Mellitus Type 1 
5.4. Genetic Basis of Type 2 Diabetes Mellitus 
5.5. Microvascular Complications 

5.5.1. Pathogenesis
5.5.2. Diabetic Retinopathy
5.5.3. Diabetic Nephropathy
5.5.4. Diabetic Neuropathy

5.6. Macrovascular Complications 

5.6.1. Ischemic Heart Disease 
5.6.2. Diabetic Cardiomyopathy 
5.6.3. Heart Failure 
5.6.4. Stroke 
5.6.5. Peripheral Arterial Disease 

5.7. Oral Antidiabetics 
5.8. Insulin Therapy 
5.9. Special Considerations 

5.9.1. Lipodystrophic Diabetes Mellitus 
5.9.2. Total Parenteral Nutrition 
5.9.3. Glucocorticoids 

5.10. Diabetes and Public Health 

5.10.1. Screening Diabetes Mellitus Type 2 
5.10.2. Prevention of Type 2 Diabetes Mellitus 

Module 6. Endocrinological Emergencies 

6.1. Thyrotoxic Crisis
6.2. Myxedematous Coma 
6.3. Non-ketotic Hyperglycemic Hyperosmolar Crisis 
6.4. Diabetic Ketoacidosis 
6.5. Acute Adrenal Insufficiency 
6.6. Hypoglycemia 
6.7. Pituitary Apoplexy 
6.8. Hypocalcemia 
6.9. Hypercalcemia 
6.10. Pediatric Endocrinologic Emergencies 

Module 7. Disorders of Intermediate Metabolism and Bone Metabolism 

7.1. Hemochromatosis 
7.2. Wilson's disease 
7.3. Porphyrias 
7.4. Disorders of Purine and Pyrimidine Metabolism 
7.5. Lysosomal Storage Diseases 

7.5.1. Pathogenesis
7.5.2. Tay-Sachs Disease 
7.5.3. Fabry’s Disease 
7.5.4. Gaucher’s Disease 
7.5.5. Niemann-Pick’s Disease 
7.5.6. Mucopolysaccharidosis 
7.5.7. Pompe’s Disease 
7.5.8. Lysosomal Acid Lipase Deficiency 

7.6. Inherited Carbohydrate Metabolism Disorders 

7.6.1. Glycogenosis 
7.6.2. Galactose Metabolism Alterations 
7.6.3. Fructose Metabolism Alterations 

7.7. Hereditary Membrane Transport Disorders 

7.7.1. Cistinuria 
7.7.2. Lisinuria 
7.7.3. Citrulinemia 
7.7.4. Hartnup's Disease 
7.7.5. Cystinosis 

7.8. Osteomalacia, Rickets and Osteogenesis Imperfecta 

7.8.1. Bone Remodeling 
7.8.2. Osteomalacia 
7.8.3. Rickets 
7.8.4. Osteogenesis Imperfecta 

7.9. Osteoporosis 

7.9.1. Epidemiology 
7.9.2. Pathophysiology
7.9.3. Diagnosis 
7.9.4. Treatment 
7.9.5. Osteoporosis Secondary to Glucocorticoids 

7.10. Paget's Disease and Other Bone Dysplasias 

7.10.1. Paget's Osteopathy 
7.10.2. Sclerosing Bone Disorders 
7.10.3. Defective Mineralization 
7.10.4. Fibrous Dysplasia 
7.10.5. Sd. McCune-Albright 

Module 8. Clinical Nutrition and Dietetics 

8.1. General Principles 

8.1.1. Assessment of Nutritional Status 
8.1.2. Nutritional Requirements 
8.1.3. Food Categories 
8.1.4. Malnutrition Markers 

8.2. Dietetics and Dietetic Therapy 

8.2.1. Dietary Recommendations 
8.2.2. Characteristics of the Different Types of Diets 
8.2.3. Nutritional Requirements 

8.3. Enteral Nutrition

8.3.1. Methods and Mechanisms of Dosage 
8.3.2. Indications, Contraindications and Complications 

8.4.    Parenteral Nutrition 

8.4.1. Types 
8.4.2. Routes and Mechanisms of Dosage 
8.4.3. Indications, Contraindications and Complications 
8.4.4. Nutrients in Parenteral Nutrition 
8.4.5. Preparation of Mixtures for Parenteral Nutrition 

8.5. Dietary and Pharmacological Treatment of Obesity 

8.5.1. Pre-treatment Assessment 
8.5.2. Modifications in Caloric Content 
8.5.3. Modification of Dietary Macronutrients 
8.5.4. Specific Role in the Control of Obesity 
8.5.5. Pharmacological Treatment of Obesity 

8.6. Diabetes Mellitus 

8.6.1. Objectives 
8.6.2. Types of Diet 
8.6.3. Strategies in Nutrition 
8.6.4. Recommended Caloric Intakes 
8.6.5. Macronutrient Distribution 
8.6.6. Other Nutrients 

8.7. Nutritional Aspects of Hyperlipemia 

8.7.1. Influence of Fatty Acids on Cardiovascular Risk 
8.7.2. Effects of Sterols on Cardiovascular Risk 
8.7.3. Recommendations to Reduce the Impact of an Atherogenic Diet 
8.7.4. Other Nutritional Recommendations 

8.8. Hydrosaline Metabolism 

8.8.1. Sodium Controlled Diet 
8.8.2. Potassium Controlled Diet 
8.8.3. Diet in Arterial Hypertension 

8.9. Nutrition in Gastrointestinal Pathologies 

8.9.1. Diet in Celiac Disease 
8.9.2. Diet and Hepatobiliary Disease 
8.9.3. Diet and Inflammatory Bowel Disease 
8.9.4. Lactose Intolerance 
8.9.5. Probiotics, Prebiotics, Symbiotics and Fiber 

8.10. Nutrition and Renal Pathology 

8.10.1. Malnutrition as a Morbimortality Factor 
8.10.2. Nutritional Assessment in the Renal Patient 
8.10.3. Nutritional Recommendations 
8.10.4. Nutritional Treatment 

Module 9. Women and endocrinology 

9.1. Physiology of the Menstrual Cycle 
9.2. Amenorrhea 

9.2.1. Classification 
9.2.2. Primary Amenorrhea 
9.2.3. Secondary Amenorrhea 

9.3. Polycystic Ovary Syndrome and Chronic Anovulation 
9.4. Hyperandrogenism and Hirsutism 
9.5. Hyperprolactinemia 
9.6. Gestational Diabetes 
9.7. Endocrinology of Pregnancy 

9.7.1. Pituitary Hormones 
9.7.2. Thyroid hormones 
9.7.3. Sex Hormones 
9.7.4. Placental Hormones 

9.8. Hormonal Contraception 
9.9. Hormones and Reproduction 
9.10. Climacteric 

9.10.1. Hormonal Changes 
9.10.2. Clinical Manifestations 

    9.10.2.1. Vasomotor Symptoms 
    9.10.2.2. Menstrual Alterations 
    9.10.2.3. Psychological Sphere 

9.10.3. Osteoporosis and Menopause 
9.10.4. Cardiovascular Disease and Menopause 
9.10.5. Hormone Replacement Therapy 

Module 10. Miscellaneous 

10.1. Gonadal Pathology 

10.1.1. Male Hypogonadism 
10.1.2. Male Hypergonadism 

10.2. Endocrinologic Diseases in the Elderly 

10.2.1. Endocrinological Changes in Aging 
10.2.2. Endocrinopathies in the Elderly 
10.2.3. Diabetes Mellitus in Older Adults 
10.2.4. Thyroid Diseases in the Elderly 

10.3. Endocrine Neoplasms of the Pancreas 
10.4. Carcinoid Syndrome 
10.5. Paraneoplastic Endocrinopathies 
10.6. Arterial Hypertension of Endocrine Origin 
10.7. Gastrointestinal Hormones in the Control of Dietary Intake 

10.7.1. Anorexigenic Hormones 
10.7.2. Orexigenic Hormones 

10.8. Central Nervous System and Hormones 

10.8.1. Thyroid Hormones 
10.8.2. Steroids 
10.8.3. Testosterone 

10.9. Short Stature: Diagnostic Approach and Therapeutic Basis 

10.10. Endocrine System and Heart 

10.10.1. Pituitary and Cardiovascular System 
10.10.2. Cushing's Syndrome and Cardiovascular Disease 
10.10.3. Thyroid and Cardiovascular System 
10.10.4. Parathyrin and Cardiovascular System 
10.10.5. Adrenal Gland and Cardiovascular System

Module 11. Hypothalamic-Pituitary Tumor Pathology

11.1. Pathogenesis of Pituitary Tumors
11.2. Clinical and Prognostic Classification of Sellar Tumors: List Clinical, Radiologic, Functional and Anatomic Pathology Elements to Characterize the Prognosis of Sellar Lesions.

11.2.1. Adenomas

    11.2.1.1. Clinical, Functional and Radiological Classification
    11.2.1.2. Pathologic Anatomy of Pituitary Adenomas

11.2.2. Non-adenomatous Sellar Tumors: Rathke's Pouch (Cysts, Craniopharyngiomas), Meningiomas
11.2.3. Non-proliferative Lesions: Inflammatory, Hemorrhagic

11.3. Imaging Study of Hypothalamic-Pituitary Tumor Pathology
11.4. Ophthalmologic Assessment of Hypothalamic-Pituitary Tumor Pathology
11.5. Prolactinoma Differential Diagnosis of Hyperprolactinemia
11.6. Acromegaly
11.7. ACTH-dependent Cushing's Syndrome Cushing's Disease
11.8. Non-functioning Pituitary Adenomas and Gonadotropinomas
11.9. Less Common Pituitary Adenomas

11.9.1. Thyrotropinomas. Multi-hormonal Adenomas
11.9.2. Aggressive Pituitary Adenomas

11.10. Other Lumps of the Sellar Region

11.10.1. Rathke's Pouch Cyst and Craniopharyngioma
11.10.2. Meningioma Pituicytoma

11.11. Surgical Treatment of Sellar and Parasellar Lesions

11.11.1. Surgical Treatment
11.11.2. Postoperative Hypothalamic-Pituitary Functional Evaluation

11.12.    Radiotherapy and Radionuclide Therapy for Sellar and Parasellar Lesions

11.12.1. Radiotherapy
11.12.2. Radionuclide Therapy
11.12.3. Long-term Monitoring after Radiotherapy

11.13. Importance of the Tumor Committee and Patient Associations

11.13.1. Multidisciplinary Approach
11.13.2. Role of Patients' Associations Association of Patients Affected by Acromegaly

Module 12. Thyroid Nodule Management. Parathyroid Tumors

12.1. Causes of Nodular Thyroid Disease Thyroid Incidentaloma
12.2. Assessment of Nodular Thyroid Disease Data that Should Lead us to Suspect Malignancy

12.2.1. Clinical Data, Personal and Family History
12.2.2. Scanning Data Laboratory Data

12.3. Ultrasound in the Assessment of Nodular Thyroid Disease

12.3.1. Cervical Ultrasonography
12.3.2. TIRADS Classification. ATA Classification

12.4. Thyroid Scan Other Imaging Techniques
12.5. Cytological Study of Nodular Thyroid Disease

12.5.1. Fine Needle Aspiration Puncture (FNA) with Ultrasound Monitoring
12.5.2. Bethesda Classification

12.6. Hyperthyroidism Caused by a Hyperfunctioning Thyroid Nodule Hyperfunctioning Multi-nodular Goiter Treatment
12.7. Usefulness of Molecular Markers What to do with Bethesda III?
12.8. Surgical Treatment of Nodular Thyroid Disease

12.8.1. Indications
12.8.2. Types of Treatment

12.9. Other treatments

12.9.1. Ethanolization
12.9.2. Laser Thermal Ablation
12.9.3. Radiofrequency Thermal Ablation

12.10. Approach to Primary Hyperparathyroidism

12.10.1. Classification
12.10.2. Biochemical Diagnosis
12.10.3. Imaging Tests
12.10.4. Treatment

Module 13. Differentiated Thyroid Carcinoma (DTC)

13.1. Molecular Aspects of Differentiated Thyroid Carcinoma Clinical Implications
13.2. Pathologic Anatomy of Thyroid Carcinoma Classification
13.3. Follicular Neoplasia with Papillary-like Changes (FNFTP)
13.4. Papillary Microcarcinoma

13.4.1. Is it Possible to Perform Surveillance Only?
13.4.2. When to Treat?
13.4.3. How to Treat?

13.5. Initial Staging 8th Classification Differences with the 7th Classification
13.6. Surgical Treatment

13.6.1. Initial Surgical Treatment
13.6.2. Treatment of Relapse

13.7. Radioiodine Treatment

13.7.1. When to Treat?
13.7.2. Treatment Dosage
13.7.3. Refractoriness to Radioiodine

13.8. Monitoring Dynamic Risk Staging
13.9. Treatment of Advanced Unresectable DTC
13.10. Importance of the Tumor Committee and Patient Associations

13.10.1. Multidisciplinary Approach
13.10.2. Role of Patients’ Associations AECAT

Module 14. Medullary Thyroid Carcinoma Other Thyroid Carcinomas

14.1. Medullary Thyroid Carcinoma (MTC)

14.1.1. Introduction. Epidemiology    
14.1.2. Classification. Anatomopathological Characteristics
14.1.3. Clinical manifestations
14.1.4. Genetic Study

14.2. MTC: Initial Staging Dynamic Risk Staging
14.3. Diagnosis of MTC

14.3.1. Laboratory Tests
14.3.2. Imaging Tests
14.3.3. FNA with Ultrasound Control

14.4. MTC. Surgical Management

14.4.1. Extent of the Surgery
14.4.2. Surgical Treatment of Recurrence
14.4.3. Surgical Treatment of Metastases

14.5. MTC. Radiotherapy Radionuclide Treatment
14.6. MTC. Treatment of an Advanced Unresectable Disease

14.6.1. Tyrosine Kinase Inhibitors
14.6.2. Other Treatments

14.7. CMT. Follow up Prognosis
14.8. Poorly Differentiated Thyroid Carcinoma Anaplastic Carcinoma
14.9. Thyroid Lymphoma and Other Rare Malignant Thyroid Tumors Metastasis of Other Tumors

Module 15. Tumors of the Adrenal Cortex

15.1. Adrenal Incidentaloma Diagnostic Approximation
15.2. ACTH-independent Cushing's Syndrome Caused by Adrenal Adenoma
15.3. Primary Hyperaldosteronism Crohn's Disease
15.4. Adrenocortical Carcinoma (ACC)

15.4.1. Introduction
15.4.2. Clinical History and Examination

15.5. ACC. Genetic Aspects Laboratory Data Hormone Secretion
15.6. ACC. Imaging Tests Ultrasound. CT, MRI, PET-CT
15.7. ACC. Pathologic Anatomy. Staging. Prognostic Factors
15.8. Surgical Management

15.8.1. Surgical Treatment of the Primary Tumor
15.8.2. Surgery and Other Local Treatments for an Advanced Disease

15.9. Adjuvants Radiotherapy Treatment of Relapse
15.10. Treatment for an Advanced Disease

Module 16. Pheochromocytomas and Paragangliomas

16.1. Introduction

16.1.1. Anatomy Recap
16.1.2. Epidemiology

16.2. Molecular Bases Genotype-Phenotype Correlation
16.3. Clinical Manifestations Forms of Presentation
16.4. Laboratory Data
16.5. Imaging Tests
16.6. Surgical Management

16.6.1. Adrenergic Blockade
16.6.2. Surgery of Pheochromocytomas and Paragangliomas Embolization

16.7. Radionuclide Therapy Radiotherapy
16.8. Treatment for an Advanced Disease
16.9. Prognosis and Monitoring

16.9.1. Monitoring of Carriers for the Various Mutations
16.9.2. Long-Term Monitoring
16.9.3. Prognosis

16.10. Importance of the Tumor Committee and Patient Associations

16.10.1. Multidisciplinary Approach
16.10.2. Role of Patients' Associations

Module 17. Multiple Endocrine Neoplasia Syndromes

17.1. Multiple Endocrine Neoplasia type 1 (MEN1) Genetics

17.1.1. MEN 1 Genetics
17.1.2. When to Conduct a Genetic Study to Rule Out Mutation in the Menin Gene?
17.1.3. Genetic Counseling in MEN 1 Preimplantation Diagnosis

17.2. Clinical Manifestations of the Syndrome MEN 1 Presentation Forms
17.3. Laboratory Tests in the Initial Assessment and Subsequent Follow-Up
17.4. MEN 1. Imaging Tests in the Initial Assessment and Subsequent Follow-Up
17.5. MEN 1. Treatment of Primary Hyperparathyroidism (PHPT) Relapse Management
17.6. MEN 1. Pancreatic Neuroendocrine Tumors Surgical Indications
17.7. Management of Other Tumors

17.7.1. NER of Atypical Locations: Bronchial and Thymic NERs
17.7.2. Screening, Monitoring and Treatment of Other Neoplasms

17.8. Multiple Endocrine Neoplasia Type 2 (MEN 2) MEN2 Genetics

17.8.1. Oncogen RET
17.8.2. Genotype-Phenotype Correlation
17.8.3. Less Common Mutations

17.9. MEN 2. Spinal Cord Carcinoma

17.9.1. Assessment and Monitoring After Learning the Carrier Status
17.9.2. Prophylactic Thyroidectomy

17.10. MEN2. MEN2

17.10.1. Assessment and Monitoring After Learning the Carrier Status
17.10.2. Indications for Treatment of Hyperparathyroidism in Patients with MEN 2
17.10.3. Other Manifestations of MEN2

17.11. MEN2. Other Manifestations of MEN2
17.12. Other Multiple Endocrine Neoplasia Syndromes

Module 18. Gastroenteropancreatic Neuroendocrine Tumors (GEPNET)

18.1. Gastroenteropancreatic Neuroendocrine Tumors

18.1.1. Epidemiology

18.2. Molecular and Cellular Bases
18.3. Pathologic Anatomy/Pathogenesis

18.3.1. Classification Systems

18.4. Lung and Thymus NER
18.5. Gastric NERs
18.6. Intestinal NERs. Appendiceal NER
18.7. Non-functioning Pancreatic NERs
18.8. Gastrinoma
18.9. Insulinoma.
18.10. Gucagonoma Somatostatinoma Vipoma Other Functioning Tumors

Module 19. GEPNET. Anatomical and Functional Diagnosis. Locoregional Disease Treatment

19.1. Carcinoid Syndrome Carcinoid Heart Disease
19.2. Syndromes of Ectopic Secretion of ACTH and Other Hormones
19.3. Diagnosis and Monitoring of GEPNETs Biological Markers

19.3.1. Usefulness in Diagnosis and Monitoring

19.4. Diagnosis and Monitoring of GEPNETs Endoscopy and Echoendoscopy-guided Fine Needle Aspiration Puncture (FNA) in the Diagnosis and Monitoring of GEPNETs

19.5. Diagnosis and Monitoring of GEPNETs Imaging Tests I

19.5.1. Ultrasound, Computerized Tomography, Magnetic Resonance Imaging
19.5.2. Response to Treatment Criteria (RECIST, Choi, others, etc.)

19.6. Diagnosis and Monitoring of GEPNETs. Other Imaging Tests II: Nuclear Medicine in the Diagnosis and Follow-up of GEPNETs
19.7. Surgical Treatment of Lung NERs
19.8. Surgical Treatment of Gastric NERs 
19.9. Surgical Treatment of Intestinal NERs
19.10. Surgical Treatment of Pancreatic NERs

19.10.1. Treatment of Incidentally Discovered Non-Functioning Pancreatic NERs: Surgery/Monitoring

19.11.  Surgical Treatment of G3 Tumors Surgical Treatment of MINEN

Module 20. Gastroenteropancreatic Neuroendocrine Tumors. Treatment for an Advanced Disease

20.1. Surgical Treatment of an Advanced Disease

20.1.1. Indication for Surgical Treatment of the Primary Tumor
20.1.2. Surgical Treatment of Liver Metastases and Other Metastases

20.2. Locoregional Treatments

20.2.1. Embolization
20.2.2. Radiofrequency
20.2.3. Other Locoregional Treatments

20.3. Biological Treatments: Somatostatin Analogues and Others
20.4. Chemotherapy and Targeted Therapies Role of Immunotherapy
20.5. Teragnosis Radionuclide Treatment
20.6. Treatment Sequencing
20.7. Nutritional Management of the Patient with GEPNET
20.8. Importance of the Tumor Committee and Patient Associations

20.8.1. Multidisciplinary Approach
20.8.2. Role of Patients' Associations NET Spain

There is not a more in-depth and updated program than this one to catch up on the large transformations that endocrinology has undergone in recent years"